Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium
- PMID: 19124515
- DOI: 10.1158/1055-9965.EPI-08-0510
Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium
Abstract
Introduction: Before the introduction of vaccination against human papillomaviruses (HPV) as a new strategy of combating cervical cancer, it is required to describe the baseline prevalence of HPV infection as well as the distribution of the different HPV types in the population and among women with cervical lesions.
Materials and methods: Approximately 10,000 liquid cervical cell samples from women, resident of Flanders (North Belgium) and participating in cervical cancer screening, were assessed cytologically and virologically with a multiplex real-time PCR using primers targeting the E6/E7 genes of 16 HPV types. Correlations of HPV infection with age, geographic area, and occurrence of cytologic lesions were assessed.
Results: The prevalence of cytologic abnormalities was atypical squamous cells of undetermined significance (ASC-US), 1.6%; atypical glandular cells (AGC), 0.2%; low-grade squamous intraepithelial lesion (LSIL), 2.6%; atypical squamous cells, HSIL cannot be excluded (ASC-H), 0.3%; and high-grade squamous intraepithelial lesion (HSIL), 1.2%. The frequency of high-risk HPV infections was 11% in women without cytologic abnormalities, 77% in ASC-US, 32% in AGC, 85% in LSIL, and 93% in ASC-H and HSIL. The prevalence of high-risk HPV infection was highest in women of ages 20 to 24 years (29%) and decreased progressively with age. The percentage of women with HSIL in the entire study population attributable to infection with a particular type (AR(pop) %) was highest for HPV16 (32%), followed by HPV31 (22%), HPV39 (11%), and HPV52 (11%). HPV18 was responsible for 7% of the HSIL lesions. Elimination of HPV16 and HPV18 is expected to reduce the prevalence of ASCUS with 24%, AGC with 19%, LSIL with 29%, ASC-H with 31% and HSIL with 37%.
Discussion: Compared to other West European studies, the prevalence of HPV infection was considerably higher in cytologically negative women but similar in women with cervical lesions. These differences could be due to the use of a PCR with high analytic sensitivity. These data are relevant for estimating the expected and theoretical levels of vaccine protection offered as vaccinated girls gradually age into the groups from which our observations stem. Further periodic laboratory-based surveys, including genotyping of cervical cell samples and linkage with vaccine registries, are an important resource to address pending questions of the effect of HPV vaccination. Research is warranted to disentangle the causal role of individual HPV types in case of multiple infections.
Similar articles
-
Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.Cancer. 2002 Apr 15;94(8):2199-210. doi: 10.1002/cncr.10439. Cancer. 2002. PMID: 12001118
-
[Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].Mikrobiyol Bul. 2008 Apr;42(2):273-82. Mikrobiyol Bul. 2008. PMID: 18697425 Turkish.
-
Risk factors for cervical neoplasia in Denmark.APMIS Suppl. 1998;80:1-41. APMIS Suppl. 1998. PMID: 9693662
-
A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination.Vaccine. 2008 Jun 2;26(23):2811-7. doi: 10.1016/j.vaccine.2008.03.047. Epub 2008 Apr 11. Vaccine. 2008. PMID: 18450340 Review.
-
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases.Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34. doi: 10.1016/j.vaccine.2006.05.026. Epub 2006 Jun 2. Vaccine. 2006. PMID: 16950015 Review.
Cited by
-
Long-term persistence of immune response to the AS04-adjuvanted HPV-16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-9-year follow-up phase III open-label study.Asia Pac J Clin Oncol. 2020 Dec;16(6):392-399. doi: 10.1111/ajco.13398. Epub 2020 Aug 11. Asia Pac J Clin Oncol. 2020. PMID: 32780946 Free PMC article. Clinical Trial.
-
Strategic Significance of Low Viral Load of Human Papillomavirus in Uterine Cervical Cytology Specimens.Diagnostics (Basel). 2022 Jul 31;12(8):1855. doi: 10.3390/diagnostics12081855. Diagnostics (Basel). 2022. PMID: 36010208 Free PMC article.
-
Monitoring of human papillomavirus vaccination.Clin Exp Immunol. 2011 Jan;163(1):17-25. doi: 10.1111/j.1365-2249.2010.04268.x. Epub 2010 Nov 9. Clin Exp Immunol. 2011. PMID: 21062269 Free PMC article. Review.
-
Ano-Genital Warts and HIV Status- A Clinical Study.J Clin Diagn Res. 2017 Jan;11(1):WC01-WC04. doi: 10.7860/JCDR/2017/24610.9171. Epub 2017 Jan 1. J Clin Diagn Res. 2017. PMID: 28274028 Free PMC article.
-
High-risk human papillomavirus infection in HIV-positive African women living in Europe.J Int AIDS Soc. 2013 Feb 14;16(1):18023. doi: 10.7448/IAS.16.1.18023. J Int AIDS Soc. 2013. PMID: 23406965 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous